title: Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
abstract: Several studies have proposed an optimal dopamine D2 receptor occupancy by antipsychotics (OOc) to establish optimal pharmacological treatment of schizophrenia. However, there are limitations to the use of the OOc, especially in application to patients with treatment-resistant schizophrenia, including dopamine supersensitivity psychosis (DSP) or late-onset psychosis (LOP). It has been suggested that D2 receptor density is up-regulated by chronic treatment of antipsychotics in DSP, whereas it may be low in LOP owing to age-related reduction. In estimation of the proposed OOc, these alterations have not been taken into account, which may be one of the factors contributing to the limited application of this index. We here hypothesize that there is an optimal range in the number of D2 receptors available for dopamine binding to elicit adequate neurotransmission in the treatment of patients with schizophrenia. We then estimated the OOc under the assumption that the range is constant while D2 density is variable. The results showed that the OOc and plasma level of antipsychotics increase with an increase in the D2 density but decrease with a decrease in the D2 density. That is, if the range of OOc is 65% to 78% in a standard D2 density, it becomes 82% to 89% under 2-fold up-regulated density and 42% to 63% under a 40% reduced density. The results also indicated that the reduction of the plasma antipsychotic level is greater during a given time period in patients with higher D2 density, as they need a higher antipsychotic dose to achieve the raised OOc, which would account for the clinical features of DSP, for example, acute exacerbation after a discontinuation of antipsychotics. On the other hand, in patients with lower D2 density, only a lower antipsychotic dose will achieve the OOc, and a small increase in the dose will result in a greater increase in occupancy and induce extrapyramidal adverse effects more easily. Furthermore, the reduction of the plasma antipsychotic level during the time period is smaller, which prolongs extrapyramidal adverse effects after discontinuation of antipsychotics in LOP. We also attempted to develop a strategy for the prevention and treatment of patients with DSP or LOP by focusing on D2 density.
authors.affiliation: Department of Psychiatry, Graduate School of Medicine, Division of Clinical Neuroscience, Center for Forensic Mental Health, Graduate School of Medicine, Chiba University, Chiba, Japan. iyom@faculty.chiba-u.jp
authors.forename: Masaomi
authors.initials: M
authors.lastname: Iyo
authors.forename: Shigenori
authors.initials: S
authors.lastname: Tadokoro
authors.forename: Nobuhisa
authors.initials: N
authors.lastname: Kanahara
authors.forename: Tasuku
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Tomihisa
authors.initials: T
authors.lastname: Niitsu
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Watanabe
authors.forename: Kenji
authors.initials: K
authors.lastname: Hashimoto
mesh_terms: D017668:Age of Onset; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000503:physiopathology; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2; D004298:Dopamine